Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Syed Jaffery

Pain Medicine Taylor, TX Medical Doctor

NPI 1487187084 CMS profile 11300206

305 Mallard Ln, Taylor, TX 76574

Open in the dashboard

General payments

$10,724

220 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Syed Jaffery of Taylor, TX is reported in the CMS Open Payments database as having received $10,724 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,951 43
2024 General $2,032 48
2023 General $2,638 85
2022 General $3,697 36
2021 General $406 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Jaffery
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Syed Jaffery were reported at $1,951. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Syed Jaffery Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $406 $399 $112–$1,219 $132
2022 $3,697 $455 $137–$1,484 $149
2023 $2,638 $484 $128–$1,495 $160
2024 $2,032 $498 $131–$1,540 $164
2025 $1,951 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $3,238 95 payments
  2. Medtronic, Inc. $2,695 49 payments
  3. Boston Scientific Corporation $2,168 20 payments
  4. Relievant Medsystems, Inc. $1,025 9 payments
  5. Foundation Fusion Solutions, LLC $422 7 payments
  6. Nalu Medical, Inc. $283 6 payments
  7. Spinal Simplicity, LLC $232 14 payments
  8. SPR Therapeutics, Inc $190 3 payments
  9. Curonix LLC $125 6 payments
  10. Globus Medical, Inc. $116 1 payment
  11. Other $231 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,523 208 payments
  2. Travel and Lodging $1,108 10 payments
  3. Entertainment $93 2 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $1,660 58 payments
  2. INTELLIS ADAPTIVESTIM $1,293 21 payments
  3. Superion Indirect Decompression System $1,201 8 payments
  4. Intracept Pain $1,078 10 payments
  5. PROCLAIM Neuromodulation $875 8 payments
  6. SYNCHROMEDII $661 6 payments
  7. Intracept Pain $630 7 payments
  8. Intracept Pain $630 7 payments
  9. Intracept Pain $630 7 payments
  10. INCEPTIV $543 15 payments
  11. Other $3,364 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,225

Median for Pain Management: 951

Drug cost

$29,487

Median for Pain Management: $26,034

Branded share of claims

45.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 434 $13,122
Pregabalin Generic 150 $3,152
Buprenorphine Generic 12 $2,869
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 78 $2,094
Lidocaine Generic 19 $1,850
Gabapentin Generic 121 $1,823
Methocarbamol Generic 71 $931
Tramadol Hcl Generic 107 $814
Acetaminophen-Codeine Acetaminophen With Codeine Brand 48 $813
Tizanidine Hcl Generic 58 $609

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$119,787

Of which drugs: $2,962

Medicare patients

489

Average age 69

Services billed

2,232

289 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 44%
Depression 31%
Chronic kidney disease 27%
Ischemic heart disease 24%
COPD 21%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 14 451 $2,683
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 44 455 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record